TG103 clinical trials
Also written TG103.
How each study uses TG103 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (9) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses TG103 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusCompletedPhase 3CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06235086Written as TG103
- A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes MellitusCompletedPhase 3CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06258148Written as TG103
- A Study of TG103 Injection in Non-diabetic Overweight or ObesityCompletedPhase 3CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT05997576Written as TG103 22.5 mg
- A Study of TG103 Injection in the Management of Non-diabetic Overweight or ObesityCompletedPhase 2CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06226090Written as TG103 7.5 mg
- A Study of TG103 Injection in Overweight/Obese Subjects Without DiabetesCompletedPhase 1CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT04855292Written as TG103 injection
- A Study of TG103 Injection in Type 2 Diabetes SubjectsStatus unknownPhase 2CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT05348122Written as TG103,Q2W
- A Study of TG103 Injection in Overweight or ObesityStatus unknownPhase 2CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT05299697Written as TG103 15 mg
- A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male SubjectsCompletedPhase 1CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT04839744Written as TG103 produced by the modified manufacturing process
- A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 DiabetesStatus unknownPhase 2CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT05063253Written as TG103
- A Study of TG103 in Subjects With Type 2 DiabetesStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04790006Written as TG103
- A Study of TG103 in Chinese Healthy Adult SubjectsCompletedPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT03990090Written as TG103